Regulation of osteoclast differentiation is key to understanding the pathogenesis and to developing treatments for bone diseases such as osteoporosis. To gain insight into the mechanism of the receptor activator of nuclear factor (NF)-B ligand (RANKL)-specific induction of the osteoclast differentiation program, we took a suppression-subtractive hybridization screening approach to identify genes specifically induced via the RANKL-Rac1 signaling pathway. Among identified targets, we show that RANKL selectively induces cyclooxygenase (COX) 2 expression via Rac1 that results in turn in production of prostaglandin E 2 (PGE 2 ) in RAW 264.7 cells. By using transient transfection assays, we found that the ؊233/ ؊206 region of the COX-2 promoter gene was critical for RANKL-induced promoter activity. This RANKL-responsive region contained an NF-B site that, when mu- 
Introduction
Bone remodeling depends on a delicate balance between bone formation and bone resorption, wherein bone-forming osteoblasts and bone-resorbing osteoclasts play central roles. 1 Tipping this balance in favor of osteoclasts leads to pathologic bone resorption, as seen in bone diseases such as autoimmune arthritis and postmenopausal osteoporosis. 2 Thus, the investigation of the regulatory mechanisms of osteoclast differentiation is critical to understand the physiology and pathology of the skeletal system.
Receptor activator of nuclear factor (NF)-B ligand (RANKL; also called TRANCE [tumor necrosis factor-related activationinduced cytokine], ODF [osteoclast differentiation factor], and OPGL [osteoprotegrin ligand]), a member of the tumor necrosis factor (TNF) family, [3] [4] [5] [6] plays an essential role in osteoclastogenesis, and its signaling mechanism has been extensively studied. 7 Briefly, binding of RANKL to its receptor, RANK, results in the recruitment of TNF receptor-associated factor (TRAF) family proteins such as TRAF6, which, in turn, activates the NF-B and Jun kinase (JNK) pathways. RANKL also induces c-Fos by an as yet unknown mechanism. The essential role of the TRAF6 and c-Fos pathways in osteoclastogenesis determined by gene targeting studies has been well documented. 8, 9 In addition, several negative regulators of RANKL signaling have been reported. [10] [11] [12] A typical example is osteoprotegerin (OPG), which functions as a soluble decoy receptor for RANKL, thereby attenuating excessive RANKL signaling.
To gain insight into how osteoclasts differentiate and function to control bone metabolism, we took a suppression-subtractive hybridization (SSH) screening approach to identify genes specifically induced via RANKL-Rac1 signaling pathway. In this screening, we found that cyclooxygenase 2 (COX-2) is one of the strongly induced genes following RANKL stimulation in osteoclast precursors. COX-2 is known to be expressed at very low levels and is strongly induced by proinflammatory stimuli, including lipopolysaccharide (LPS), as well as by several activated oncogenes. 13, 14 The significance of COX-2 in inflammation is highlighted by the observation that COX-2 inhibitors block the synthesis of prostaglandin (PG) E 2 (PGE 2 ) and, as a result, inhibit inflammation and confer analgesia. 15 In bone, PGE 2 is produced mainly by osteoblasts and acts as a potent stimulator of bone resorption. 16 The production of PGE 2 by osteoblasts is regulated by several cytokines, including interleukin 1 (IL-1) and IL-6. The addition of indomethacin, an inhibitor of PG synthesis, to mouse bone marrow cultures strikingly suppresses osteoclast formation induced by IL-1, indicating that PGE 2 production by osteoblasts is involved in the mechanism of bone resorption induced by IL-1. 17, 18 In the inflammatory processes, in which the mononuclear phagocyte family plays a crucial part, PGs by themselves have little inflammatory capacity, but in the presence of other mediators they can synergistically amplify the local inflammatory responses. 19, 20 Because the rate-limiting step in PGE 2 synthesis is catalyzed by COX-2, 21 the fact that osteoclast precursors express COX-2 by RANKL stimulation led us to the investigation of direct involvement of PGE 2 in osteoclast differentiation induced by RANKL signaling.
Here, we provide evidence that COX-2 expression is dependent on RANKL-regulated small guanosine triphosphatase (GTPase) Rac1 pathway. We also show that RANKL stimulation results in the production of PGE 2 , which contributes to the accelerated osteoclast differentiation. We further demonstrate that the ability of Rac1 to regulate COX-2 expression depends on NF-B, a key regulator of COX-2 transcription. Finally, we show that inhibition of COX-2 by celecoxib severely suppresses differentiation of bone marrowderived monocyte/macrophage cells (BMMs) into tartrate-resistant acid phosphatase-positive (TRAP ϩ ) osteoclasts. This inhibition can be rescued by the addition of exogenous PGE 2 . Collectively, our results show that RANKL-Rac1-NF-B-dependent COX-2 expression plays a key role in the RANKL-induced osteoclast differentiation via PGE 2 production.
Materials and methods

Cell culture and reagents
The RAW264.7 monocyte/macrophage cell line was maintained at 37°C in 5% CO 2 atmosphere in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). RAW264.7 cells stably transfected with a cDNA encoding a dominant-negative mutant of Rac1, RacN17 (RAW-RacN17), were maintained in DMEM supplemented with 10% FBS and 400 g/mL G418. Celecoxib, purchased from LKT Laboratories (Minneapolis, MN), was dissolved in dimethyl sulfoxide (DMSO) as a 100-mM stock solution and stored at Ϫ20°C. Recombinant macrophage colony-stimulating factor (M-CSF) was purchased from R&D Systems (Minneapolis, MN); RANKL was from PeproTech (London, United Kingdom); and all other chemicals were from Sigma (St Louis, MO). Anti-COX-2 (C-20) was from Santa Cruz Biotechnology (Santa Cruz, CA).
In vitro osteoclastogenesis
Nonadherent bone marrow-derived monocytes/macrophages cells (BMMs) derived from C57BL/6 mice were seeded and cultured in ␣-minimal essential medium (␣-MEM; Gibco, Grand Island, NY) with 10% FBS containing 10 ng/mL M-CSF. After 2 days, nonadherent cells including lymphocytes were washed out, and adherent cells were used as BMMs. These osteoclast precursor cells were further cultured in the presence of 50 ng/mL RANKL and 10 ng/mL M-CSF to generate osteoclasts. After 5 days of culture, cells were fixed and stained for tartrate-resistant acid phosphatase (TRAP). TRAP ϩ multinucleated (Ͼ 3 nuclei) cells were counted as osteoclast-like cells. The cells were observed with a Zeiss Axiovert 200 microscope (Carl Zeiss, Oberkochen, Germany) equipped with a PlanNeofluor 20ϫ/0.50 objective lens (Carl Zeiss), and images were obtained with an AxioCam HR (Carl Zeiss) using AxioVision 3.1 software (Carl Zeiss).
Subtractive hybridization and differential screening
Total RNA was prepared using TRIzol reagent (Gibco). Then, 1 mg total RNA was subjected into an Oligotex poly A ϩ RNA column (Qiagen, Valencia, CA) to purify poly A ϩ RNA. Then, 2 g poly A ϩ RNA from RANKL-treated RAW264.7 and RAW-RacN17 cells was used to make tester and driver cDNAs. Subtracted polymerase chain reaction (PCR) was performed using the PCR-select cDNA subtraction kit according to the manufacturer's protocol (Clontech, Palo Alto, CA). Briefly, tester and driver cDNAs were digested with RsaI, and the tester was ligated to adapter DNA. After 2 hybridizations with the tester and driver cDNAs, the resulting mixture was diluted 1:1000 and amplified by PCR using flanking and nested primers to produce a subtracted and normalized PCR fragment library. The efficiency of subtraction was verified via Southern blot analysis of the unsubtracted and subtracted PCR products using a 32 P-labeled glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA probe. Subtracted PCR products were cloned into pGEM-T easy vector (Promega, Madison, WI) for DNA sequence analysis.
Northern hybridization and immunoblotting analysis
For the Northern analysis, 20 g total RNAs extracted from RANKLtreated RAW264.7 and RAW-RacN17 cells was separated and transferred to nylon membranes as described. 4 The membranes were hybridized with ␣-32 P]dCTP probe prepared using a ready-to-go labeling kit and a ProbeQuant G-50 purification kit (Amersham Biosciences, Buckinghamshire, United Kingdom). For immunoblotting analysis, 10 6 cells of RAW264.7 and RAW-RacN17 cells were stimulated with RANKL (50 ng/mL) for the indicated times and then lysed in 20 mM HEPES (N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid), pH 7.4, 150 mM NaCl, 1% Triton X-100, 10% glycerol, and proteinase inhibitors mix for 30 minutes on ice. After centrifugation, supernatants were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes (Amersham Biosciences). The proteins were detected with specific antibodies against COX-2 and tubulin (Santa Cruz Biotechnology).
PGE 2 measurements
RAW264.7 cells and RAW-RacN17 cells were cultured for 15 hours in 96-well plates. Indomethacin (10 M) and celecoxib (100 ng/mL) were applied 30 minutes prior to RANKL (50 ng/mL) stimulation for 8 hours. The PGE 2 level was measured in cells plated 10 4 /well, using a commercially available PGE 2 enzyme immunoassay kit (Cayman Chemicals, Ann Arbor, MI).
Transient transfections and luciferase assay
Luciferase reporter pGL3 plasmid including 5Ј-flanking region (from Ϫ1838 to ϩ123 bp) of the human COX-2 gene was kindly provided by Dr S. Prescott (University of Utah, Salt Lake). DNA fragments of various lengths of the COX-2 promoter regions (Ϫ1838/ϩ123, Ϫ518/ϩ123, Ϫ361/ϩ123, Ϫ200/ϩ123, Ϫ96/ϩ123, Ϫ78/ϩ123, and Ϫ44/ϩ123) were prepared by PCR using the pGL3 plasmid as the template and subsequently subcloned into pGL3 plasmid. For luciferase assay, RAW264.7 and RAW-RacN17 cells (1 ϫ 10 7 ), suspended in 400 L serum-free medium, were mixed with 10 g pGL3-basic or pGL3-COX-2 promoter-luciferase reporter and 2 g pCMV-␤-galactosidase plasmid and electroporated (BTX, Holliston, MA) using the preset protocol for RAW264.7 cells (155 V, 70 msec, 1 pulse). Thirty hours after electroporation, RANKL (50 ng/mL) was applied for 6 hours. Cells were then harvested and lysed in a reporter lysis buffer (Promega). Luciferase value was normalized to ␤-galactosidase value. The relative luciferase value (RLV) was defined as the ratio of the COX-2 luciferase activity divided by the activity of pGL3-basic luciferase in cell lysates. The RLV of RANKL-stimulated pGL3-basic transfected cultures was given the arbitrary value of 1. The fold induction was calculated by dividing the RLV of a given culture by the RLV of the pGL3-basic control.
EMSA
RANKL-stimulated or unstimulated cells were lysed and nuclear extracts were prepared as described previously. 22 For the electrophoretic mobility shift assay (EMSA), 1 ϫ 10 5 cpm of a 32 P-end-labeled probe was incubated with a mixture of nuclear extract (5 g) in the binding buffer (10 mM Tris [tris(hydroxymethyl)aminomethane)-HCl, pH 7.5, 50 mM KCl, 1 mM dithiothreitol, 1 mM EDTA [ethylenediaminetetraacetic acid], 5% glycerol, and 2 g poly (dI-dC) plus 5% NP-40) for 15 minutes at room temperature, and the protein-DNA complexes were resolved in a 5% native polyacrylamide gel and detected by autoradiography. We used the following double-stranded probes: proximal NF-B site of wild-type probe, 5Ј-CAGGAGAGTGGGGACTACCCCCTCTGCT-3Ј (Ϫ233/Ϫ206); distal NF-B site of wild-type probe, 5Ј-GGCGGGAGAGGGGATTCCCTGCGC-CCCCG-3Ј (Ϫ457/Ϫ429); proximal NF-B site of mutant probe, 5Ј-CAGGAGAGTGGccACTACCCCCTCTGCT-3Ј; and distal NF-B site of For personal use only. on November 13, 2017. by guest www.bloodjournal.org From mutant probe, 5Ј-GGCGGGAGAGGGGATctCCTGCGCCCCCG-3Ј. A double-stranded, NF-B-specific oligonucleotide probe containing the 2 tandemly repeated NF-B sites derived from the HIV long terminal repeat (5Ј-ATCAGGGACTTTCCGCTGGGGACTTTCCG-3Ј) was also used as a control. 23 The underlined nucleotides indicate the NF-B-binding sites, and the lowercase nucleotides indicate the mutations.
Results
Identification of Rac1-dependent genes highly expressed during osteoclastogenesis on RANKL stimulation
We have recently reported that RANKL activates Rac1 in RAW264.7 cells thereby regulating osteoclast differentiation (Fig7). 24 To identify genes selectively activated by RANKL through Rac1-dependent pathway, differentially expressed genes between RANKL-stimulated RAW264.7 cells and RANKL-stimulated RAWRacN17 cells (denoted as RacN17) expressing a dominant interfering mutant RacN17 were isolated using SSH, a cDNA subtraction technique based on suppression PCR that is sensitive to rare transcripts. The subtractive cDNA libraries were constructed at the 2 different RANKL-stimulated time points (8 hours and 3 days) and were analyzed as described previously. 25 The most abundant clones chosen from the subtraction were carbonic anhydrase II, osteopontin, and cathepsin K, all of which were previously known to play critical roles in osteoclast function. 26, 27 As shown in Figure  1 , mRNAs for carbonic anhydrase II and cathepsin K, both of which are known to be strongly expressed in osteoclasts, were specifically induced by RANKL in RAW264.7 cells but not in RAW-RacN17 cells, confirming the validity of our screening protocol. Among genes that have not previously been functionally implicated in osteoclast differentiation were immune response gene (IRG) 1, 28 interferon (IFN)-inducible gene (Ifi) 202, 29 and COX-2 ( Figure 1 ). In osteoblasts, COX-2 is known to play a critical role in synthesis of PGE 2 21 thereby stimulating osteoclast differentiation indirectly. 30 Because RANKL-stimulated COX-2 induction in osteoclast precursors has not been reported previously, COX-2 was chosen for further analysis in this study.
Requirement of the Rac1 pathways in RANKL-induced COX-2 expression and PGE 2 induction
To confirm that Rac1 controls the induction of COX-2 by RANKL, we measured COX-2 expression by Northern blotting with RNA preparation from RAW264.7 and RAW-RacN17 cells at various time points after RANKL stimulation. The results showed that COX-2 induction of RAW264.7 cells was seen from 2 hours after RANKL stimulation and decreased toward basal level after 24 hours (Figure 2A ). In contrast, COX-2 induction by RANKL was significantly lower in RAW-RacN17 cells. Consistent with this result, immunoblotting analysis revealed that robust induction of COX-2 protein occurred in RAW264.7 cells but not in RAWRacN17 cells ( Figure 2B ).
To determine whether PGE 2 secretion depends on the RANKLRac1-dependent pathway, we measured the level of PGE 2 in supernatants of RAW264.7 and RAW-RacN17 cell cultures harvested before and after 8 hours of stimulation with RANKL. As shown in Figure 3A , RANKL stimulation induced PGE 2 production in RAW264.7 cells, whereas RAW-RacN17 cells were defective in PGE 2 induction by RANKL. Consistently, COX inhibitors, celecoxib and indomethacin, completely inhibited RANKLinduced PGE 2 secretion ( Figure 3B ). These data showed that COX-2 expression by Rac1-transduced signals is required for PGE 2 induction by RANKL. ) was applied to each lane. cDNAs for cathepsin K, carbonic anhydrase II, osteopontin, Ifi202, IRG1, and COX-2 were used to prepare probes and hybridized to total RNA. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as a control for total RNA loading. 
Functional activity of COX-2 promoter in response to RANKL
To explore the transcriptional regulation of COX-2 gene by RANKL stimulation, we studied the COX-2 promoter-driven transcription in RAW264.7 cells transiently transfected with DNAs containing a region spanning from Ϫ1838 to ϩ123 bp relative to the transcription start site of the human COX-2 gene in the reporter plasmid pGL3 basic (P1-1838). As shown in Figure 4A , luciferase activity of this construct was strongly up-regulated on activation by RANKL. To map the regions responsible for this induction, subsequent 5Ј-deletion constructs ranging from Ϫ518 down to Ϫ44 bp were generated ( Figure 4A ). An induction in promoter activity on RANKL stimulation was observed only in the reporter construct, P-518, indicating that a critical regulatory region at Ϫ518/ Ϫ362 bp was responsible for this induction. Sequence analysis revealed the existence of a potential distal NF-B-binding site at Ϫ457/Ϫ429 bp. 31 In contrast, the promoter activity of a shorter construct, P-361, containing a proximal NF-B-binding site at Ϫ233/Ϫ206 bp could not be induced by RANKL stimulation, suggesting that the distal NF-B-binding site but not the proximal one is important for RANKL-induced activation of COX-2 promoter.
To determine whether Rac1 regulates COX-2 promoter activity, RAW264.7 and RAW-RacN17 cells were electroporated with a reporter construct containing the luciferase gene under the control of the COX-2 promoter (P-1838) or reporter basic (pGL3-basic). After 30 hours, cells were untreated or treated with RANKL or LPS for 6 hours. Cells were then lysed and luciferase activity was measured in the lysates. The results showed that LPS increased COX-2 promoter activity in both RAW264.7 and RAW-RacN17 cells. However, RANKL activated the COX-2 promoter in RAW264.7 cells but not RAW-RacN17 cells ( Figure 4B To further analyze the functionality of these sequences as NF-B-binding elements, we performed EMSA with nuclear extracts of RAW264.7 cells using DNA probes of the 2 putative NF-B-binding sites. A retarded complex was resolved in nuclear extracts from RAW264.7 cells stimulated by RANKL with the distal NF-B probe (Ϫ457/Ϫ429) but not with the proximal probe (Ϫ233/Ϫ206; Figure 5A ). This band was not seen with a distal NF-B probe (Ϫ457/Ϫ429M) containing a mutation in the NF-Bbinding element, confirming the specificity of the reaction. As expected, the retarded complex could not be seen in RAW-RacN17 cells on RANKL stimulation ( Figure 5B ). We also performed EMSA with an oligonucleotide probe containing the 2 NF-B sites derived from the HIV long terminal repeat. Consistent with the results in RAW264.7 cells, RANKL-induced NF-B activation was severely affected in RAW-RacN17 cells ( Figure 5C ).
Inhibition of osteoclast differentiation by COX-2 inhibitors
To investigate the role of RANKL-stimulated COX-2 expression in osteoclast precursors, we examined the effect of a specific inhibitor of COX-2, celecoxib, on osteoclast differentiation of BMMs in the absence of stromal cells. Celecoxib inhibited RANKL-induced osteoclast differentiation from BMMs in a dose-dependent manner (Figure 6Aiii-v) . The similar inhibitory effect was observed with indomethacin, COX-1 and COX-2 inhibitors in BMMs (data not shown).
Because the expression of COX-2 is clearly seen within 15 hours after RANKL stimulation (Figure 2) , we next examined whether celecoxib affects the early stage or the late stage of osteoclast differentiation by performing temporal treatment with celecoxib. Addition of celecoxib 2 days after RANKL stimulation had no effect on osteoclast formation (Figure 6Avi-viii) , consistent with the fact that the early time induction of PGE 2 by RANKL stimulation is necessary for osteoclast differentiation. For personal use only. on November 13, 2017 . by guest www.bloodjournal.org From
Exogenous PGE 2 reversed the inhibitory effects of celecoxib
Celecoxib is known to inhibit COX-2, 32 the enzyme responsible for catalyzing the formation of PGE 2 from arachidonic acid. Whether the inhibitory effects of celecoxib on osteoclastogenesis are mediated through the suppression of COX-2 was investigated. To determine this, BMMs were exposed to exogenous PGE 2 together with celecoxib and then examined for RANKL-induced osteoclast differentiation. The results in Figure 7 show that suppressive effects of osteoclast differentiation by celecoxib could be reversed by PGE 2 . The latter alone had no effect on osteoclast differentiation. Thus, these results suggest that celecoxib inhibits osteoclast differentiation through the suppression of COX-2 activity, thereby resulting in the inhibition of PGE 2 induction.
Discussion
RANKL signaling is known to be essential for osteoclast differentiation, at the stage after the commitment of the bone marrow progenitor cells into the myelomonocytic lineage. 7 Although our understanding of signaling pathways associated with osteoclast differentiation advanced considerably recently, the regulatory factors of RANKL-mediated osteoclastogenesis, involved in transmission and modulation of RANKL signaling, are still unknown. By using PCR-based SSH, we have identified a COX-2 gene whose expression is highly enriched during RANKL stimulation and whose induction is impaired in RAW264.7 cells expressing a dominant-negative form of Rac1.
Our study clearly demonstrates a pathway uniquely linked to RANKL signaling, culminating in the expression of COX-2 through RANK-Rac1-NF-B-dependent pathway. Osteoclast formation induced by RANKL was accompanied by PGE 2 production, which was blocked by a selective COX-2 inhibitor celecoxib. We also showed that suppression of osteoclastogenesis by celecoxib could be reversed by PGE 2 . Moreover, simultaneous treatment with PGE 2 in the presence of RANKL cooperatively induced osteoclast differentiation. Taken together, these data show RANKL-induced COX-2 is responsible for PGE 2 production in osteoclast precursors for regulating osteoclast differentiation. PGE 2 plays a crucial role in regulation of bone resorption. 33 Agonists reported to stimulate PGE 2 -dependent osteoclast formation include IL-1, 34 TNF-␣, 35 and parathyroid hormone. 36 Most of these agonists induce PGE 2 production in osteoblasts and stromal cells, and osteoclast formation induced by these agonists is dependent on PGE 2 synthesis in mouse bone marrow cultures. 37, 38 It has also been reported that COX-2 and PGE 2 play important roles in bone formation of rat long bones as shown in an experiment using systemic injection of PGE 2 39 and are required for mesenchymal cell differentiation into osteoblasts. 40 Because of the complexity of responses to PGE 2 in bone cells including osteoclasts and osteoblasts, it is difficult to define precisely the net effect of PGE 2 on bone resorption and formation. However, our data suggest that RANKL-induced PGE 2 synthesis in osteoclast precursors is cell autonomous and that PGE 2 acts directly on the precursors for osteoclast formation in a paracrine or an autocrine manner. This is consistent with the previous finding of a synergistic effect of PGE 2 on the ability of RANKL to induce osteoclast differentiation. 41 In addition, Okada et al 42 showed a reduction in RANKL-stimulated osteoclast formation in spleen cell cultures in the absence of osteoblasts from COX-2 Ϫ/Ϫ mice, suggesting that PGE 2 originates from multiple sources during osteoclastogenesis in vivo. PGE 2 exerts its effects through interaction with specific cell surface receptors. 43 The PGE receptors, divided into 4 subtypes (EP1, EP2, EP3, and EP4), are important in regulating PGE 2 action in the target cells. Among them, EP4 and EP2 are coupled to activation of adenyl cyclase and are implicated in PGE 2 -induced osteoclastogenesis. [44] [45] [46] It is tempting to speculate that the PGE 2 -EP signaling works in osteoclast precursors to induce a maximal osteoclast formation. Evidence for expression of both EP2 and EP4 receptors in the osteoclast precursors including RAW264.7 cells and BMMs 47 supports this possibility. It remains to be clarified under what physiologic or pathologic contexts the PGE 2 -EP signaling is mobilized for bone resorption. Whatever the detailed mechanism underlying this process, our results indicate that RANKL induces COX-2 expression in osteoclast precursors through Rac1-dependent NF-B activation pathway, thereby resulting in PGE 2 production. Although PGE 2 itself is not sufficient for regulating osteoclast formation, PGE 2 likely acts in an autocrine or a paracrine loop to enhance the early phase differentiation of osteoclasts. These findings suggest that signaling molecules involved in COX-2-PGE 2 pathway in osteoclast precursors could potentially be novel targets for drugs to inhibit osteoclast function.
